Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Orthobiologic polymer resists biofilm formation

DiFusion Technologies : 31 May, 2013  (Company News)
DiFusion completes a series of in vitro tests and an in vivo study, carried out in part at Clemson University, to validate the efficacy of the company's new orthobiologic polymer - CleanFuze.


The in vivo study demonstrated that CleanFuze resists biofilm formation while third party in vitro antimicrobial testing revealed a 99.9999 percent reduction in S aureus colonies, compared to a competitive antimicrobial material - silicon nitride; which showed no antimicrobial efficacy relative to CleanFuze.



"Bacteria attach themselves to the surfaces of conventional surgical implants and form biofilms, which provide a protective environment where the microorganisms can proliferate and develop antimicrobial resistance. These studies establish the potential of CleanFuze to strongly inhibit the development of bacterial biofilm while displaying superior osteoblast adhesion when compared to conventional PEEK," according to Joe Crudden, PhD, Chief Executive Officer of DiFusion.



These types of biofilm infections are becoming all too common. "Recent high profile cases of surgical infections include the likes of Rob Gronkowski (infected plate) and Tom Brady (infected ACL screw) of the New England Patriots, both of whom have undergone multiple additional surgeries related to biofilm formation. Such surgical infections create huge additional costs for the hospitals," said Daniel George, MD, orthopaedic surgeon from New Milford Hospital in Connecticut.



"CleanFuze, a new material currently being developed for interbody devices, can be applied to any metal implant, giving it a competitive advantage over common metal implants that are susceptible to biofilm formation. This technology could potentially save millions of dollars for your average sized hospital, as penalties are phased in under ObamaCare," said Derrick Johns, Managing Director.



DiFusion plans to launch CleanFuze in the European Union via CE Mark in the Q4 of 2013. The company is in the process of selecting a global distribution partner and will launch CleanFuze in the US via 510(k) submission in 2014 following its introduction in the European Union. Professor Hans Jorg Meisel, MD, PhD, the Director for the Center of Neurosciences and the Chair of the Department of Neurosurgery at BG-Clinic Bergmannstrost, Halle, Germany, said: "An orthobiologic material that resists infection and osteointegrates with bone would be the holy grail of orthopaedics. What more could we ask of an implant or material?"


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo